Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N2O2.C2H4O2 |
Molecular Weight | 206.2395 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O.NCCCC[C@H](N)C(O)=O
InChI
InChIKey=RRNJROHIFSLGRA-JEDNCBNOSA-N
InChI=1S/C6H14N2O2.C2H4O2/c7-4-2-1-3-5(8)6(9)10;1-2(3)4/h5H,1-4,7-8H2,(H,9,10);1H3,(H,3,4)/t5-;/m0./s1
Molecular Formula | C2H4O2 |
Molecular Weight | 60.052 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C6H14N2O2 |
Molecular Weight | 146.1876 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.nap.edu/read/10490/chapter/12Curator's Comment: description was created based on several sources, including
https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373
Sources: https://www.nap.edu/read/10490/chapter/12
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/npp/lysine.html | https://www.ncbi.nlm.nih.gov/pubmed/26252373
Lysing is an essential basic amino-acid encoded by codone AAA and AAG, and used in the biosynthesis of proteins. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken. In a clinical study lysine supplements was found to be an effective for reduction of occurrence, severity and healing time for recurrent HSV infection, however Cochrane Review concluded that the evidence is insufficient. Lysine was investigated for improving anxiety, ameliorating angina prectoris. Lysine acetylsalicylate has been used to treat pain and to detoxify the body after heroin use. Lysine clonixinate has been used for its analgesic properties for the treatment of migraine headaches and other painful conditions. However, limited clinical trials exist for these conditions.
CNS Activity
Originator
Sources: https://www.drugs.com/npp/lysine.html
Curator's Comment: Lysine was first isolated from casein (a milk phosphoprotein) in 1889 by the German dentist Heinrich Drechsel
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1875 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616 |
|||
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8587651 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | L-LYSINE MONOHYDRATE Approved UseLysine has been studied for the prevention and treatment of herpes infections and cold sores. |
|||
Primary | L-LYSINE MONOHYDRATE Approved UseLysine supplements may relieve effort-related angina pectoris. |
|||
Sources: https://www.drugs.com/npp/lysine.html |
Primary | L-LYSINE MONOHYDRATE Approved UseLysine increases the intestinal absorption and reduces the renal elimination of calcium. |
||
Sources: https://www.drugs.com/npp/lysine.html |
Primary | L-LYSINE MONOHYDRATE Approved UseLysine is believed to exert anxiolytic effects by acting as a partial serotonin receptor 4 antagonist and as a partial benzodiazepine agonist |
||
Palliative | L-LYSINE MONOHYDRATE Approved UseLysine acetylsalicylate has been used to detoxify the body after heroin use. |
|||
Primary | NEOPROFEN Approved UseNeoProfen is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Launch Date2006 |
PubMed
Title | Date | PubMed |
---|---|---|
Dose-dependent protein adduct formation in kidney, liver, and blood of rats and in human blood after perchloroethene inhalation. | 1999 Mar |
|
Antibodies to SOX13 (ICA12) are associated with type 1 diabetes. | 2001 |
|
Identification of the alpha-aminoadipic semialdehyde dehydrogenase-phosphopantetheinyl transferase gene, the human ortholog of the yeast LYS5 gene. | 2001 Apr |
|
The fermentative production of L-lysine as an animal feed additive. | 2001 Apr |
|
Translational extracts active biologically in vitro obtained from eukaryotic monolayer cells: a versatile method for viral RNA studies. | 2001 Apr |
|
Properties of microtubules assembled from mammalian tubulin synthesized in Escherichia coli. | 2001 Apr 17 |
|
Peflin and ALG-2, members of the penta-EF-hand protein family, form a heterodimer that dissociates in a Ca2+-dependent manner. | 2001 Apr 27 |
|
Ethanol production from wheat straw hemicellulose hydrolysate by Pichia stipitis. | 2001 Apr 27 |
|
Biochemical and functional characterization of a molecule expressed by a subset of thymic medullary epithelial cells. | 2001 Feb |
|
Isolation of the Escherichia coli nucleoid. | 2001 Feb |
|
How does endotoxin trigger inflammation in otitis media with effusion? | 2001 Feb |
|
Purification and structure elucidation of the N-acetylbacillosamine-containing polysaccharide from Bacillus licheniformis ATCC 9945. | 2001 Feb |
|
ESR detection of intraphagosomal superoxide in polymorphonuclear leukocytes using 5-(diethoxyphosphoryl)-5-methyl-l-pyrroline-N-oxide. | 2001 Jan |
|
RNA interference is mediated by 21- and 22-nucleotide RNAs. | 2001 Jan 15 |
|
Post-transcriptional effects of extracellular pH on tumour necrosis factor-alpha production in RAW 246.7 and J774 A.1 cells. | 2001 Mar |
|
Characterisation of L-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles. | 2001 Mar 1 |
|
Quantitative analysis of specific mRNA species in minute cell samples by RT-PCR and flow cytometry. | 2001 Mar 1 |
|
Inositol phosphates from barley low-phytate grain mutants analysed by metal-dye detection HPLC and NMR. | 2001 Mar 1 |
|
Effects of initial particle size on the tableting properties of L-lysine monohydrochloride dihydrate powder. | 2001 Mar 14 |
|
Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. | 2001 Mar 15 |
|
High pressure increases bactericidal activity and spectrum of lactoferrin, lactoferricin and nisin. | 2001 Mar 20 |
|
Human corneal GlcNac 6-O-sulfotransferase and mouse intestinal GlcNac 6-O-sulfotransferase both produce keratan sulfate. | 2001 May 11 |
|
Inhibition of cytosolic phospholipase A2 by annexin I. Specific interaction model and mapping of the interaction site. | 2001 May 11 |
|
CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. | 2001 May 25 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.nap.edu/read/10490/chapter/12
Lysin is an essential amino-acid. The daily requirement for lysine is 38 mg/kg body weight. The most rich source of lysine is fish, beef, chicken.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28103616
In the in vitro study of herpes simplex virus (HSV) growth in tissue culture, arginine deficiency suppressed HSV growth. Maximum herpes growth (as measured by plaques counting) was observed in flasks, containing 10-20 ug/ml of arginine. The addition of 50 ug/ml of lysine to the flasks containing 2.5 and 5.0 ug/ml of arginine reduced the number of viable plaque-forming units (PFU) from 3300 and 48800 to less than 10.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:19 GMT 2025
by
admin
on
Mon Mar 31 17:54:19 GMT 2025
|
Record UNII |
TTL6G7LIWZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TTL6G7LIWZ
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
SUB127497
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104640
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
100000091744
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
DBSALT001763
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
TTL6G7LIWZ
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
104152
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
1371501
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
260-664-4
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
6537
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | RxNorm | ||
|
4453
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
57282-49-2
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
SUB127496
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
SUB21782
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
C66045
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY | |||
|
DTXSID80886223
Created by
admin on Mon Mar 31 17:54:19 GMT 2025 , Edited by admin on Mon Mar 31 17:54:19 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |